ArticleDiabetologia2021
Increased particle size of triacylglycerol-enriched remnant lipoproteins, but not their plasma concentration or lipid content, augments risk prediction of incident type 2 diabetes.
Article in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Hypertriglyceridemia is a dose-dependent risk factor for type 2 diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program.BMJ open diabetes research & care · 2021Trial
- Cardiometabolic risk status modifies the associations between remnant cholesterol with incident diabetes: evidence from two East Asian cohorts.Frontiers in nutrition · 2026Article
- A cross-sectional analysis of remnant cholesterol-diabetes association in US adults.Scientific reports · 2025Article
- Remnant cholesterol in early pregnancy as a predictor of gestational diabetes mellitus beyond triglyceride levels: a retrospective cohort study.BMC pregnancy and childbirth · 2025Article
- Sex differences in the association between atherogenic index of plasma and progression from normoglycemia to prediabetes: evidence from a 5-year large-scale retrospective cohort study.Frontiers in endocrinology · 2025Observational
- Lipid Transporter ABCA1 in Diabetic Polyneuropathy: Potential Mediation by Circulating Metabolites.Journal of pain research · 2025Article
- Nonlinear association between remnant cholesterol and reversion from impaired fasting glucose to normoglycemia: a multicenter cohort study.Lipids in health and disease · 2024Article
- Associations of remnant cholesterol in early pregnancy with gestational diabetes mellitus risk: a prospective birth cohort study.Lipids in health and disease · 2024Article
- Remnant cholesterol, but not other cholesterol parameters, is associated with gestational diabetes mellitus in pregnant women: a prospective cohort study.Journal of translational medicine · 2023Article
- The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus.Cardiovascular diabetology · 2022Article
- Lipoprotein particle sizes and incident type 2 diabetes: the PREVEND cohort study.Diabetologia · 2022Article
- The relationship of remnant cholesterol and abdominal obesity in children: A cross-sectional study.Frontiers in cardiovascular medicine · 2022Article
- Correlation of Triglyceride-Rich Lipoprotein Cholesterol and Diabetes Mellitus in Stroke Patients.International journal of endocrinology · 2022Article
- Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study.Cardiovascular diabetology · 2021Observational
- Effect of Weight Loss by Low-Calorie Diet on Cardiovascular Health in Type 2 Diabetes: An Interventional Cohort Study.Nutrients · 2021Article
- β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes: New Directions of Research and Novel Therapeutic Strategies.Biomedicines · 2021Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
aims/hypothesisType 2 diabetes prevention requires the accurate identification of those at high risk. Beyond the association of fasting serum triacylglycerols with diabetes, triacylglycerol-enriched remnant lipoproteins (TRLs) more accurately reflect pathophysiological changes that underlie progression to diabetes, such as hepatic insulin resistance, pancreatic steatosis and systemic inflammation. We hypothesised that TRL-related factors could improve risk prediction for incident diabetes.
methodsWe included individuals from the Brazilian Longitudinal Study of Adult Health cohort. We trained a logistic regression model for the risk of incident diabetes in 80% of the cohort using tenfold cross-validation, and tested the model in the remaining 20% of the cohort (test set). Variables included medical history and traits of the metabolic syndrome, followed by TRL-related measurements (plasma concentration, TRL particle diameter, cholesterol and triacylglycerol content). TRL features were measured using NMR spectroscopy. Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC).
resultsAmong 4463 at-risk individuals, there were 366 new cases of diabetes after a mean (±SD) of 3.7 (±0.63) years of follow-up. We derived an 18-variable model with a global AUROC of 0.846 (95% CI: 0.829, 0.869). Overall TRL-related markers were not associated with diabetes. However, TRL particle diameter increased the AUROC, particularly in individuals with HbA CONCLUSIONS/
interpretationTRL particle diameter improves the prediction of diabetes, but only in individuals with HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.